Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.61 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9098551 | 1.00 | P4HTM (0.61) | P4HTMP4HA1MIFTDP1CYP1A2 | |
| Hydrochloric Acid SCHEMBL28862169 | 0.98 | P4HTM (0.60) | P4HTMP4HA1MIFTDP1CYP1A2 | |
| SCHEMBL11410325 | 0.86 | P4HTM (0.59) | P4HTMP4HA1MIFTDP1CYP1A2 | |
| SCHEMBL6163873 | 0.83 | CYP1A2 (0.58) | P4HTMCYP1A2GAAALDH1A1KDM4E | |
| SCHEMBL41111 | 0.83 | ADRA2A (0.56) | P4HTMCYP1A2GAAALDH1A1CYP2C19 | |
| SCHEMBL5326143 | 0.83 | ALDH1A1 (0.53) | P4HTMTDP1CYP1A2GAAALDH1A1 | |
| SCHEMBL11632125 | 0.82 | P4HTM (0.56) | P4HTMP4HA1MIFTDP1CYP1A2 | |
| SCHEMBL11410824 | 0.82 | MEN1 (0.57) | P4HTMTDP1ALDH1A1KDM4EMAPT | |
| SCHEMBL11632758 | 0.82 | P4HTM (0.56) | P4HTMP4HA1MIFTDP1CYP1A2 | |
| Methane SCHEMBL28217937 | 0.81 | ADRA2A (0.54) | P4HTMCYP1A2GAAALDH1A1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41998-E1 | Compositions and methods of treatment of sympathetically maintained pain | Arclon Therapeutics, Inc. (US) | 2010-12-14 | — | — | US | claimed |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0573581-A4 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1 INC (US) | 1994-06-29 | — | — | EP | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0573581-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, Inc. (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014453-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF SYMPATHETICALLY MAINTAINED PAIN | ARC 1, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| US-12616674-B2 | Anti-fibrotic NEU3 inhibitor compounds and methods of use | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260116887-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | GUANGZHOU INNOCARE PHARMA TECH CO LTD (CN) | 2026-04-30 | — | — | US | disclosed |
| EP-4731306-A1 | CYSTOBACTAMID DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-12606544-B2 | JAK1 selective kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-4764522-A | ANTIDEPRESSANT, ANTIPARKINSON DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1988-08-16 | — | — | US | disclosed |
| CN-85107182-A | Process for preparing monoamide derivatives of ethylenediamine | — | 1987-04-08 | — | — | CN | disclosed |
| EP-0053789-B1 | 2-PYRIDINECARBOXAMIDE DERIVATIVE, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION, USEFUL AS AN ANTI-ALLERGIC AGENT | Tanabe Seiyaku Co., Ltd. (JP) | 1985-03-27 | — | — | EP | disclosed |
| US-4404214-A | 2-Pyridinecarboxamide derivatives compositions containing same and method of using same | TANABE SEIYAKU CO., LTD. (JP) | 1983-09-13 | — | — | US | disclosed |
| EP-0053789-A1 | 2-Pyridinecarboxamide derivative, process for preparing same and pharmaceutical composition, useful as an anti-allergic agent | Tanabe Seiyaku Co., Ltd. (JP) | 1982-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | P4HTM 1761/4885P4HA1 1023/4885MIF 4115/4885 |
| US-20260116887-A1 | HETEROCYCLIC COMPOUNDS FOR MEDIATING TYROSINE KINASE 2 ACTIVITY | TYK2, JAK2, JAK1 | P4HTM 2536/4885P4HA1 2764/4885MIF 3179/4885 |
| US-12606544-B2 | JAK1 selective kinase inhibitor | JAK1, JAK2, JAK3 | P4HTM 4068/4885P4HA1 1427/4885MIF 4014/4885 |
| US-12616674-B2 | Anti-fibrotic NEU3 inhibitor compounds and methods of use | NEU3, NEU2, NEU1 | P4HTM 1984/4885P4HA1 921/4885MIF 865/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | P4HTM 257/4885P4HA1 167/4885MIF 4264/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | P4HTM 296/4885P4HA1 258/4885MIF 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.